These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8296190)

  • 1. [How long should cyclosporin be administered following bone marrow transplantation?].
    Gratwohl A; Tichelli A; Stauffer G; Passweg J; Pless M; Gengenbacher D; Buser U; Signer E; Haberthür C; Gimmi C
    Schweiz Med Wochenschr; 1994 Jan; 124(1-2):44-50. PubMed ID: 8296190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMT for severe aplastic anemia using cyclosporine.
    May WS; Sensenbrenner LL; Burns WH; Ambinder R; Carroll MP; Griffin CA; Jones RJ; Miller CB; Mellits ED; Vogelsang GB
    Bone Marrow Transplant; 1993 Jun; 11(6):459-64. PubMed ID: 8334426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
    Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
    Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation.
    Gillio AP; Boulad F; Small TN; Kernan NA; Reyes B; Childs BH; Brochstein JA; Laver J; Castro-Malaspina H; O'Reilly RJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):18-24. PubMed ID: 9209737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
    Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M
    Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
    Arranz R; Conde E; Rodriguez-Salvanés F; Pajuelo FJ; Cabrera R; Sanz MA; Petit J; Bueno J; Maldonado J; Odriozola J; Conde JG; Brunet S; Carreras E; Iriondo A; Fernández-Rañada JM; Marín P;
    Bone Marrow Transplant; 2002 Feb; 29(3):205-11. PubMed ID: 11859392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.
    Hernández-Boluda JC; Marín P; Carreras E; Aguilar JL; Grañena A; Rozman C; Montserrat E
    Haematologica; 1999 Jan; 84(1):26-31. PubMed ID: 10091390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria.
    Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Benvenuto F; Figari O; Mordini N; Berisso G; Bregante S; Frassoni F; Bacigalupo A
    Haematologica; 2000 Jan; 85(1):59-62. PubMed ID: 10629593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
    Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.